Open label comparison of injectable buprenorphine (CAM2038 Brixadi ) and naltrexone (Vivitrol ) for opioid use disorder

Recruiting

99 years and younger

All

Phase 2

200 participants needed

1 Location

Brief description of study

Compare brain fMRI response to injectable extended-release buprenorphine (Brixadi, XR-BUP) and naltrexone (XR-NTX, Vivitrol) Our primary outcome combines adherence to treatment and the frequency of illicit opioid use during treatment. The primary outcome is a binary indicator of treatment success: Participants who provide 2 weekly UDS positive for opioids or reports of two or more periods of 3 days of opioid use in the 3rd (last) month of treatment, is late for more than 2 weeks for XRNTX or XRBUP treatment, or drops out of treatment prior to the 3rd injection, will be classified as treatment failures; otherwise, they will be classified as a treatment success. Test an integrated brain-behavior model of relapse vulnerability in OUD; ASI composite scores; effects of Group and neural change variables on other substance use outcomes

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
opioid use disorder
Age: - 99 Years
Gender: All

Updated on 30 Apr 2024. Study ID: 843403

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).